Partner Newcastle Premier Health (NPH) carried out both one-way and two-way validation of the technology
Catenae Innovation PLC (LON:CTEA) said its partner Newcastle Premier Health has successfully completed a proof-of-concept pilot trial of the Cov-ID app.
Cov-ID is GDPR compliant identity documentation exchange system to record an individual’s coronavirus (COVID-19) test status through a mobile application. The project is a joint initiative by a consortium of companies led by the Z/Yen Group, and it is expected the fully validated product will be rolled out to businesses.
Newcastle Premier Health (NPH) carried out both one-way and two-way validation of the app.
For the former, the QR code was readable by any device equipped with scanner functionality or app. Two-way validation allowed the gatekeeper and the certificate holder to use the app.
Catenae’s interim chief executive, Guy Meyer, said he was “really pleased” with the result.
And he added that the scope of the pilot trial was ambitiously expanded midway through to include the one-way validation usage on top of the initial two-way authentication.
“Some minor graphic design refinements, based on NPH’s feedback, will be completed within the next three weeks,” Meyer said in a statement.
“Then the Cov-ID app will be ready to be rolled out commercially across the UK and beyond to the benefit of businesses and organisations alike as the nations of the world begin to return to a semblance of normality.”